Three poststroke hemiplegic patients were treated by injecting Botulinum toxin A (BtxA) into the subscapularis muscle, to reduce pain and increase the range of motion in the shoulder. According to the described procedure, 250 units of Dysport toxin were injected through a 0.8-mm diameter needle with electrostimulation guidance. In the 3 cases, injection of BtxA reduced pain and improved the range of motion, especially abduction and external rotation, of the hemiplegic shoulder. This result confirms the role of spasticity in hemiplegic shoulder pain and the beneficial effects of Botulinum toxin injection into the subscapularis muscle deserve to be confirmed in further series.

Keywords:
Shoulder pain, Hemiplegia, Stroke, Spasticity, Botulinum toxin A
1.
Bohannon RW, Larkin PA, Smith MB, Horton MG: Shoulder pain in hemiplegia: Statistical relationship with five variables. Arch Phys Med Rehabil 1986;67:514–516.
2.
Geurts ACH, Visschers BAJT, van Limbeek J, Ribbers GM: Systematic review of aetiology and treatment of post-stroke hand oedema and shoulder hand syndrome. Scand J Rehabil Med 2000;32:4–10.
3.
Van Ouwenaller C, Laplace PM, Chantraine A: Painful shoulder in hemiplegia. Arch Phys Med Rehabil 1986;67:23–26.
4.
Caldwell CB, Wilson DJ, Braun RM: Evaluation and treatment of the upper extremity in the hemiplegic stroke patient. Clin Orthop 1969;63:69–93.
5.
Braun RM, West F, Mooney V, Nickel VL, Roper B, Caldwell C: Surgical treatment of the painful shoulder contracture in the stroke patient. J Bone Joint Surg Am 1971;53:1307–1312.
6.
Chironna RL, Hecht JS: Subscapularis motor point block for the painful hemiplegic shoulder. Arch Phys Med Rehabil 1990;71:428–429.
7.
Hecht JS: Subscapular nerve block in the painful hemiplegic shoulder. Arch Phys Med Rehabil 1992;73:1036–1039.
8.
Chang YW, Hughes RE, Su FC, Itoi E, An KN: Prediction of muscle force involved in shoulder internal rotation. J Shoulder Elbow Surg 2000;9:188–195.
9.
Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C: A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000;31:2402–2406.
10.
Bhatka BB, Cozens JA, Chamberlain MA, Bamford JM: Impact of botulinum toxin A on care burden due to arm spasticity after stroke: A randomized, double-blind, placebo-controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217–221.
11.
Simpson DM, Alexander DN, O’Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP: Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306–1310.
12.
Smith SJ, Ellis E, White S, Moore AP: A double-blind, placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000;14:5–13.
13.
Bohannon RW, Smith MB: Inter-rater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206–207.
14.
Snels IA, Beckerman H, Twisk JW, Dekker JH, De Koning P, Koppe PA, Lankhorst GJ, Bouter LM: Effect of triamcinolone acetonide injections on hemiplegic shoulder pain: A randomized controlled trial. Stroke 2000;31:2396–2401.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.